🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

126 results for “Pfizer Ireland Pharmaceuticals Unlimited Company” Clear

  1. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  2. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  3. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  4. CT7001, PF-07850327 round

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. DIPHENHYDRAMINE HYDROCHLORIDE, PF-06835375 Injection

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Primary immune thrombocytopenia

    phase 2 small molecule active

    1 trial

  7. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  8. Disitamab Vedotin

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  9. ELRANATAMAB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  10. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. FULVESTRANT, LETROZOLE

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HR-positive HER2-negative metastatic/advanced BC

    phase 2 small molecule active

    1 trial

  12. Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 100 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)

    phase 2 small molecule active

    1 trial

  13. IPILIMUMAB, AXITINIB, PF-08634404, AXITINIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  14. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  15. LETROZOLE, FULVESTRANT

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  16. Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  17. Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  18. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  19. PF-07850327 round

    Pfizer Ireland Pharmaceuticals Unlimited Company

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  20. PF-07868489

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  21. PF-07915503, PF-07915503, PF-07915503, Etrasimod Arginine Blue, PF-07915503

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  22. PF-08049820, PF-08049820, Placebo for PF-08049820

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  23. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. Placebo for pf-07328948 tablet (CCI) mg, Placebo for pf-07328948 tablet (CCI) mg

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Heart failure

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources